Xilio Therapeutics, Inc.: 5%+ holders

As of November 6, 2026, 7 holders' latest Schedule 13D or 13G filings report owning 5% or more of Xilio Therapeutics, Inc. The largest reported stake is Gilead Sciences, Inc.'s, at 19.9%. 14 filings are on record since August 14, 2025 (Schedule 13G/A, February 12, 2026).

Bain Capital Life Sciences Fund II, L.P. also filed stake reports on 2 other companies ↓

Sell to companies like Xilio Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filing 2026-08-14 · Reporting person: StemPoint Capital LP · Sole voting: 0 · Shared voting: 628,866 · Sole dispositive: 0 · Shared dispositive: 628,866 · SCHEDULE 13G/A, 2026-08-14
• Filed 2026-05-15 · Holder: Sirenia Capital Management LP · Percent: 9.9% · SCHEDULE 13G
• Filed 2026-05-15 · Holder: Point72 Asset Management, L.P. · Percent: 0% · SCHEDULE 13G/A
• Filed 2026-05-15 · Holder: Orbimed Advisors LLC · Percent: 9.99% · SCHEDULE 13G
• Filed 2026-05-15 · Holder: BCLS II Equity Opportunities, LP · Percent: 9.99% · SCHEDULE 13G/A

Xilio Therapeutics, Inc. has 14 Schedule 13D or 13G filings on record since 2025-08-14. 7 holders' latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind Xilio Therapeutics, Inc. and the warning signs.

See Xilio Therapeutics, Inc.'s free Snapshot Watch Xilio Therapeutics, Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on Xilio Therapeutics, Inc. and the records around it.

Xilio Therapeutics, Inc. elsewhere on the record

• Who owns it

Companies that share a holder

• Bain Capital Life Sciences Fund II, L.P. also filed stake reports on 2 other companies: C4 Therapeutics, Inc. (Oct 2025)
• StemPoint Capital LP also filed stake reports on 4 other companies: Cellectar Biosciences, Inc. (Aug 2026), Faeth Therapeutics, Inc. (Aug 2026), Surrozen, Inc. (Aug 2026)
• GILEAD SCIENCES, INC. also filed stake reports on 5 other companies: Aspen Neuroscience, Inc. (Nov 2026), Arcus Biosciences, Inc. (Aug 2026), ASSEMBLY BIOSCIENCES, INC. (May 2026)

Want the whole picture on Xilio Therapeutics, Inc.?

Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)

A Full Report on Xilio Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Xilio Therapeutics, Inc. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   16 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies Xilio Therapeutics, Inc. by CUSIP 98422T209 and gives its principal executive office as 828 Winter Street, Suite 300, Waltham, MA 02451 (SCHEDULE 13G/A, 2026-08-14).

Timeline

Swipe the table sideways to see every column.

Questions about who owns Xilio Therapeutics, Inc.

Who owns Xilio Therapeutics, Inc.?

On this page, 7 holders' latest ownership filings report 5% or more of Xilio Therapeutics, Inc.: Gilead Sciences, Inc. (19.9%, Schedule 13G/A, filed 2026-02-12), Coastlands Capital LP (9.99%, Schedule 13G, filed 2025-12-11), BCLS II Equity Opportunities, LP (9.99%, Schedule 13G/A, filed 2026-05-15), Orbimed Advisors LLC (9.99%, Schedule 13G, filed 2026-05-15) and Sirenia Capital Management LP (9.9%, Schedule 13G, filed 2026-05-15); 2 more are listed above.

Who are the largest shareholders of Xilio Therapeutics, Inc.?

By the share each holder's latest filing reports, the largest holders of Xilio Therapeutics, Inc. on this page are Gilead Sciences, Inc. (19.9%), Coastlands Capital LP (9.99%) and BCLS II Equity Opportunities, LP (9.99%).

When did Gilead Sciences, Inc. buy into Xilio Therapeutics, Inc.?

The filings give report dates, not purchase dates. The earliest filing from Gilead Sciences, Inc. on this page is the Schedule 13G/A, filed 2025-08-14, reporting 19.9%; its latest, Schedule 13G/A filed 2026-02-12, reports 19.9%. That earliest filing is itself an amendment, which updates an earlier report.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 14 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Also on the record for Xilio Therapeutics, Inc.

Swipe the table sideways to see every column.

Tools for this story

Each opens in a new tab, filled in for Xilio Therapeutics, Inc.. With no account yet, you sign up free and land on the result.

• Get an alert when Xilio Therapeutics, Inc. is mentioned again
• Find former Xilio Therapeutics, Inc. employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes